Wir sind mit live! Mehr erfahren
AXNX-Symbol

Axonics, Inc. Common Stock
AXNX

Nicht mehr börsennotiert

AXNX wurde am 14. November 2024 von der Börse genommen.

Zurück zu den Rankings
 

Profil: Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.

Mitarbeiter: 797

Gesundheitswesen Medizinische Geräte und Verbrauchsmaterialien

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 0 %
Neutral 0 %
Negativ 0 %
Positiv
Zacks Investment Research
letztes Jahr
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates
Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ago.
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates
Neutral
Business Wire
letztes Jahr
Axonics Reports Third Quarter 2024 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2024. “Axonics continued to execute at a high level in the third quarter, generating revenue growth of 25% year over year,” said Raymond W. Cohen, chief executive officer. “Revenue growth for both sacral.
Axonics Reports Third Quarter 2024 Financial Results
Neutral
Zacks Investment Research
vor 2 Jahren
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device
AXNX's R20 rechargeable SNM system, offering long-lasting treatment for bladder and bowel dysfunction, gains approval in Australia.
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device
Neutral
Business Wire
vor 2 Jahren
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder and fecal incontinence. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once.
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia
Positiv
Zacks Investment Research
vor 2 Jahren
Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic
AXNX stock continues to gain following a favorable court ruling last week in a patent litigation with Medtronic.
Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic
Neutral
Business Wire
vor 2 Jahren
Axonics Prevails in Patent Infringement Lawsuit with Medtronic
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the Central District of California. The jury found that Axonics does not infringe any of the three patents-in-suit. “A jury of our peers recognized that Axonics' proprietary tined lead design and temperature sensor technology is differentiated from our competitor's intellect.
Axonics Prevails in Patent Infringement Lawsuit with Medtronic
Positiv
Zacks Investment Research
vor 2 Jahren
Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates
Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.15 per share a year ago.
Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates
Neutral
Business Wire
vor 2 Jahren
Axonics Reports Second Quarter 2024 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended June 30, 2024. “Axonics continued to execute at a high level in the second quarter, generating record revenue and setting new high-water marks for gross margin and adjusted EBITDA margin,” said Raymond W. Cohen, chief.
Axonics Reports Second Quarter 2024 Financial Results
Neutral
Business Wire
vor 2 Jahren
Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ recharge-free sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder. “Approval of the Axonics recharge-free system is welcome news for Australians with bladder and bowel dysfunction,” said Dr. Ailsa Wilson Edwards, a urologist at Calvary North Adelaide Hospital. “I.
Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
Neutral
Business Wire
vor 2 Jahren
Axonics Reports First Quarter 2024 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024. “Our commercial team continued to execute at a high level in the first quarter, generating revenue growth of 29% year over year across our portfolio of incontinence products,” said Raymond W. Cohen, chief executive.
Axonics Reports First Quarter 2024 Financial Results
Nachrichtenrankings ansehen
Kursdiagramme mit Lightweight Charts™ umgesetzt